ATX01 15%

AlgoTherapeutix · Phase 2 active Small molecule

At a glance

Generic name	ATX01 15%
Sponsor	AlgoTherapeutix
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy and Safety of ATX01 in Adult Patients With CIPN (Chemotherapy-induced Peripheral Neuropathy) (PHASE2)
EASE (Efficacy of ATX01 Study in Erythromelalgia) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ATX01 15% CI brief — competitive landscape report
ATX01 15% updates RSS · CI watch RSS
AlgoTherapeutix portfolio CI